Delayed contrast extravasation MRI: a new paradigm in neuro-oncology
Open Access
- 30 November 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (3), 457-465
- https://doi.org/10.1093/neuonc/nou230
Abstract
Conventional magnetic resonance imaging (MRI) is unable to differentiate tumor/nontumor enhancing tissues. We have applied delayed-contrast MRI for calculating high resolution treatment response assessment maps (TRAMs) clearly differentiating tumor/nontumor tissues in brain tumor patients. One hundred and fifty patients with primary/metastatic tumors were recruited and scanned by delayed-contrast MRI and perfusion MRI. Of those, 47 patients underwent resection during their participation in the study. Region of interest/threshold analysis was performed on the TRAMs and on relative cerebral blood volume maps, and correlation with histology was studied. Relative cerebral blood volume was also assessed by the study neuroradiologist. Histological validation confirmed that regions of contrast agent clearance in the TRAMs >1 h post contrast injection represent active tumor, while regions of contrast accumulation represent nontumor tissues with 100% sensitivity and 92% positive predictive value to active tumor. Significant correlation was found between tumor burden in the TRAMs and histology in a subgroup of lesions resected en bloc (r2 = 0.90, P < .0001). Relative cerebral blood volume yielded sensitivity/positive predictive values of 51%/96% and there was no correlation with tumor burden. The feasibility of applying the TRAMs for differentiating progression from treatment effects, depicting tumor within hemorrhages, and detecting residual tumor postsurgery is demonstrated. The TRAMs present a novel model-independent approach providing efficient separation between tumor/nontumor tissues by adding a short MRI scan >1 h post contrast injection. The methodology uses robust acquisition sequences, providing high resolution and easy to interpret maps with minimal sensitivity to susceptibility artifacts. The presented results provide histological validation of the TRAMs and demonstrate their potential contribution to the management of brain tumor patients.Keywords
This publication has 38 references indexed in Scilit:
- Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRIClinical Neurology and Neurosurgery, 2010
- Imaging of Brain Tumors: MR Spectroscopy and Metabolic ImagingNeuroimaging Clinics of North America, 2010
- Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with GlioblastomaRadiology, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Enhancing Fraction in Glioma and Its Relationship to the Tumoral Vascular Microenvironment: A Dynamic Contrast-Enhanced MR Imaging StudyAmerican Journal of Neuroradiology, 2009
- Pseudoprogression and pseudoresponse in the treatment of gliomasCurrent Opinion in Neurology, 2009
- Magnetic Resonance Perfusion and Permeability Imaging in Brain TumorsNeuroimaging Clinics of North America, 2009
- Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendationsSurgical Neurology, 2009
- Posttreatment Recurrence of Malignant Brain Neoplasm: Accuracy of Relative Cerebral Blood Volume Fraction in Discriminating Low from High Malignant Histologic Volume FractionRadiology, 2009
- Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging MeasurementsAmerican Journal of Neuroradiology, 2008